Artiva Biotherapeutics Prioritizes Refractory Rheumatoid Arthritis as Lead Indication for AlloNK (AB-101)

Artiva Biotherapeutics Inc. (NASDAQ:ARTV) is one of the Reddit stocks that will go to the moon. On October 16, Artiva Biotherapeutics announced that it prioritized refractory rheumatoid arthritis/RA as the lead indication for the development of its allogeneic, off-the-shelf NK cell therapy candidate, AlloNK (AB-101). The prioritization reflects the significant unmet need among the over 100,000 refractory RA patients in the US who have exhausted existing treatment options.

AlloNK is designed to enhance the activity of B-cell-targeting monoclonal antibodies/mAbs, such as rituximab, through antibody-dependent cellular cytotoxicity/ADCC to achieve deep and durable B-cell depletion, a mechanism that could lead to long-term durable responses. Artiva has received a major regulatory designation, with the US FDA granting Fast Track Designation to AlloNK for the treatment of refractory RA in combination with rituximab.

AlloNK is believed to be the first drug candidate in the emerging deep B-cell depleting therapeutic category, which includes CAR-T and T-cell engagers, to receive this designation in refractory RA. The company plans to conduct regulatory interactions with the FDA in H1 2026 to align on a pivotal trial design. The engagement could position AlloNK as the first therapy in its category to advance to a pivotal trial for refractory RA patients.

Artiva Biotherapeutics Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company that develops natural killer/NK cell-based therapies for patients suffering from autoimmune diseases and cancers.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.